1. Home
  2. PLRX vs XBIT Comparison

PLRX vs XBIT Comparison

Compare PLRX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

70.6M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.31

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLRX
XBIT
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.6M
74.4M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
PLRX
XBIT
Price
$1.13
$2.31
Analyst Decision
Hold
Analyst Count
4
0
Target Price
$2.67
N/A
AVG Volume (30 Days)
437.4K
32.7K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
29.97
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$2.09
52 Week High
$1.95
$3.61

Technical Indicators

Market Signals
Indicator
PLRX
XBIT
Relative Strength Index (RSI) 43.54 41.99
Support Level $1.12 $2.26
Resistance Level $1.37 $2.67
Average True Range (ATR) 0.04 0.05
MACD 0.00 0.00
Stochastic Oscillator 26.67 15.61

Price Performance

Historical Comparison
PLRX
XBIT

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: